In this video, InMed CEO Eric A. Adams speaks with BTV about InMed’s focus on cannabinoid-based pharmaceutical products. Mr. Adams talks about the company’s proprietary biosynthesis platform with potential to manufacture pharmaceutical-grade, high-yield cannabinoids.
In the Media
Eric A. Adams talks with BTV about InMed’s biosynthesis of cannabinoids
Share this post
Latest Media News
In this video, InMed Pharmaceuticals CEO Eric A. Adams speaks about the company’s ocular disease program. INM-088 is a cannabinol (CBN) formulation showing potential to
InMed’s therapeutic development of cannabinol and update on programs – Executive Interview with CEO Eric A. Adams
In this video, InMed Pharmaceuticals’ CEO Eric A. Adams speaks about the company’s therapeutic development of cannabinol (CBN), a rare cannabinoid showing potential to treat